打國光疫苗的後果，需大家幫忙！！！

[pfge]

轉貼：H1N1 注射後... 請大家幫忙
(請各位網友到受害者的姊姊部落格加油打氣，相關資料可直接貼上去。)

這是我妹妹

就是電視新聞報導的小四生(務必要看影片：住院時 腳抽蓄 ＆ 復健中 腳有如小兒麻痺)

我很無助

看到爸媽為妹妹奔波

而我只能旁觀

我不知道能做什麼

台灣

我妹不是第一案例

也不是最後一個案例

妹妹發病坐輪椅時

我推著她

她細聲跟我說 姊姊我現在很醜對不對 ? 別人會笑我對不對? 我想上課！

當下我真的好痛心好痛心

一個舞蹈隊的小孩

一個大隊接力老是跑最後一棒的女孩

一個家裡的開心果

一個出門老被誇漂亮的女孩

打完針才得了H1N1 就變這樣

我不懂醫療

只知道出院當下要要病例 要不到是有問題

只知道一直逼問我父母家族病歷史是有問題

只知道大大小小單位天天打電話來關心，有點像做壞是虛心的小孩

我無權批評任何說法

畢竟我只是一個不起眼的高職生

我不知道發這篇文章會有什麼後果

只是要大家看

打完有機會變成那樣

你願意打嗎?


疾管局只會排除再排除...

請問 你們是把觀民眾健康還是國光製造商倒不倒?


如果你願意

請把文章傳給他人

(這供參考)

打不打請自己三思



但我需要幫忙

我想了解外國對疫苗打完是否有副作用

想了解 前疾管局局長說的試驗是不是如他所說? 美國死亡達一萬人 是不是因為有問題才不敢打?

http://tw.news.yahoo.com/article/url/d/a/091219/128/1x7p6.html (新聞)

我想請大家幫我尋找國外對疫苗的看法 說詞

有資料請留言給我

謝謝大家。

http://pfge-pfge.blogspot.com/2009/12/blog-post_19.html

[Mary Lee]

加拿大兒童在接種第二剤的佐劑 H1N1疫苗之後的不良反應/ 發燒處理:

6-35個月的兒童在打完 第二劑的Pandemrix H1N1病毒疫苗之後反應原性(因預防注射而引起的免疫系統的不良反應)增加了。 注意：Pandemrix是葛蘭素史克AS03被批准在歐洲使用的疫苗, 可比Arepanrix™*

不良反應 ------------------ -----第一劑接種後----第二劑接種後
疼痛------------------------------31.4 %--------- 41.2％
發紅 --------------------------- --19.6 %--------- 29.4％
膨脹 ------------------------------15.7 %--------- 23.5％
發燒:攝氏 38度或高於38度/ 腋溫------- 5.9％-----------43.1％
發燒:攝氏 39度或高於39度）/ 腋溫------ 0.0％-----------3.9％
昏睡------------------------------ 7.8％------- ---35.3％
易怒----------------------------- 21.6 %---------- 37.3％
食慾不振---------------------- -----9.8 %---------- 39.2％

在接種第二剤的佐劑 H1N1疫苗之後,發燒在38度或高於38度的風險大幅上升。提醒家長接種後發燒的可能性，提供必要的發燒處理的資料。

預防接種後發燒處理:

*解熱劑，例如對乙酰氨基酚acetaminophen (Tylenol)一（15-20毫克/公千/劑量）可每隔4至5個小時給一次，如果持續發燒，在24小時內不可超過五劑。

*建議溫水拭浴，休息及飲水。

*不要給兒童含有乙酰水楊酸（ASA）例如: (Asprin) 阿司匹靈的產品，因為 Reye綜合徵的風險。

瑞氏綜合徵是一種潛在致命的疾病, 導致大量器官的損害，特別是大腦和肝臟，以及引起低血糖。確切原因不明，雖然它一直跟兒童因病毒性疾病而使用阿司匹靈有關，但它也發生在沒有使用阿司匹靈。早期診斷是至關重要的，而大部分兒童經支持性治療而康復，重度顱腦損傷或死亡，是潛在性的併發症。

Increased Reactogenicity following 2nd dose of Pandemrix H1N1® in children 6-35 months NOTE: Pandemrix is the GSK AS03 vaccine approved for use in Europe and comparable to Arepanrix


Adverse reactions------------------Post dose 1----Post dose 2
Pain ------------------------------31.4 %---------41.2%
Redness---------------------------19.6%---------29.4%
Swelling---------------------------15.7%---------23.5%
Fever ( > 38º C ) axillary-------5.9% --------43.1%
Fever ( > 39ºC ) axillary-------0.0% ---------3.9%
Drowsiness--------------------------7.8% ------- 35.3%
Irritability--------------------------21.6%----------37.3%
Loss of appetite----------------------9.8%----------39.2%


Risk of fever ≥ 38º C increased substantially after second dose of adjuvanted A/H1N1 vaccine *Alert parents to likelihood of fever after immunization, provide fever management information as needed

Management of fever following immunization:

*Antipyretics, e.g. acetaminophen (15-20mg/kg/dose) may be given at intervals of 4 to 5 hours if fever persists, not to exceed five doses in 24 hours.

*Tepid sponge baths, rest and fluids recommended

*Do not give products containing acetylsalicylic acid (ASA) to children because of the risk of Reye syndrome.

Source: BCCDC Communicable Disease Control Immunization Program Manual, Section IX

[Mary Lee]

加拿大H1N1病毒流感疫苗監測報告 - 接種後不良反應事件

更新：2009年12月18日

所有在加拿大被授權使用的疫苗的安全性都經過精心測試。而已經被授權使用的H1N1流感疫苗，是根據初步的臨床實驗數據，由於疫苗的施打是全國性的因此疫苗會被繼續監測和測試。

加拿大公共衛生局和加拿大衛生部協同各省和地區，加拿大兒科協會和網絡的研究人員一起正在積極地監測所有在加拿大因接種H1N1病毒流感疫苗後所產生的不良反應事件。這是加拿大政府參予確保疫苗安全性以及做為提供H1N1型流感疫苗安全性定期報告的主要因素。

加拿大公共衛生局是利用現有的系統 - 加拿大接種後不良事件監測系統（CAEFISS）。 CAEFISS藉醫療專業人員的支持,醫療專業人員將不良反應事件報給省/地區公共衛生辦公室，然後共享信息與加拿大接種後不良事件監測系統 。

這現行制度同時受到其它方案的支持以提供更詳細的資料，特別是有關 H1N1病毒流感疫苗。這些包括：

*免疫監測方案::是由一個兒童教學醫院經網絡報告兒童免疫接種後的嚴重不良反應事件。在每個參與站點，護士監測尋找和報告任何免疫接種後的不良反應事件。
*嚴重的成果監測（SOS）的網絡就像免疫監測方案網絡，但會密切留意成人住院治療。該系統必要的話還可以用在監測其他的症狀, 疾病或失調。
再則*加拿大公共衛生局的 - 加拿大國立衛生研究院流感研究網絡（PCIRN）會監測疫苗的安全性在不同的團體和背景，包括兒童，原住民，愛滋病帶原者，醫療工作人員及對雞蛋過敏的人。

現有的監測系統，加上其他額外的方案的支持將有助於加拿大公共衛生局監測疫苗接種後不良反應事件，針對疑慮發現任何可能的信號，並決定，如果有，是否與疫苗有關。

藥品或疫苗上市後的監測, 對使用後的不良反應做了國際上公認的定義 ：

免疫接種後不良反應事件（預防接種副作用): 任何不必要的醫療接種後的反應, 大多數不良反應反應事件並不嚴重，包括注射部位的疼痛，腫脹或紅腫; 發燒; 紅疹; 頭痛;; 肌肉疼痛。

免疫接種後嚴重的不良反應事件: 任何不良反應事件, 是危及生命，或導致死亡，需要住院治療，延長現有的住院或導致輕度殘疾(無法執行一個或多個重要的日常生活功能)。

嚴重的接種後不良反應事件是罕見的。在任何免疫接種活動，從常規兒童疫苗季節性流感疫苗的報告率嚴重不良反應事件是在大約 1例，平均每10萬個劑量分佈。

在1: 100 000 的比率是基於幾千萬支疫苗分發了數年。這個比率是根據政府的幾種不同類型的疫苗，其中一些高或低利率的不良反應事件。比率可以按年齡也各不相同。欲了解更多信息，請訪問我們的疫苗安全性和監視常見問題。

定期報告從這些來源提供了一個早期預警系統，可以幫助加拿大公共衛生局識別是否有需要作進一步調查，以確保疫苗的安全性。

本報告包含的不良反應事件總計資料是由各省和各地區和其他來源報告給加拿大公共衛生局的。它提供了一個數字的統計分析,分析有關被通報的嚴重不良反應事件以及選定的嚴重不良反應事件的特殊重要性，如過敏性反應（一種嚴重的過敏反應），總率的不良反應事件報告是是以每10萬劑疫苗，分佈在加拿大。

不良反應事件的報告並不意味著該疫苗是有問題的。小心謹慎的調查是必要的，以確定事件是否與疫苗有直接旳關聯或沒有。在每週特寫裡被通報的不良反應事件和嚴重不良反應事件這個數字是根據進一步的調查結果，因此數字會隨時間而改變。流行性感冒的風險遠遠超過了流感疫苗接種的風險。

每週特寫

截至2009年12月5日，2千1百10萬9千劑量的3種疫苗已經分佈在加拿大：

* Arepanrix（混合型H1N1流感疫苗由葛蘭素史克）一(混合型=佐劑型)
*甲型流感（H1N1）2009大流行的單價疫苗（無佐劑由葛蘭素史克）
* Panvax（非混合型H1N1流感疫苗的流動通訊澳大利亞）一(非混合型=無佐劑型)

打從H1N1流感疫苗注射活動開始，一直到 12月5日，共有4331不良反應事件已通報給省和地區的免疫計劃，其中132案件中符合了一個或一個以上的規定條件而被認定為嚴重。而 84例過敏案件則被包括在嚴重的不良反應事件其中。

本報告的不良反應率每10萬個劑量分佈是20.5。該報告率嚴重不良反應事件是0.63每10萬劑量分佈。迄今為止，H1N1病毒免疫接種後產生過敏總頻率每10萬個劑量分佈是為0.40，不超過在接受任何疫苗後所觀察到的正常範圍。

分析

詳細審查的監測數據，這點繼續支持安全的疫苗。H1N1病毒流感疫苗不良反應事件總的報告率是高於季節性流感疫苗，而嚴重不良反應事件報告率是一致的平均約 1例，每10萬劑量分佈。有幾個因素促成 H1N1病毒流感疫苗報告率，其中包括：

*H1N1流感疫苗被引起廣大的注意，是由於前線醫護人員都增加了他們的警覺性，並報告更多的潛在的不良反應。醫院裡增加的監測，同時也收集到更多的報告。
*無庸至疑的, 過敏是免疫接種一個嚴重不良反應事件風險，嚴重過敏性反應，一般發生在接種疫苗幾分鐘之內，當疫苗接種者還在門診時。過敏案件是最經常被通報的，也是最容易被發現的嚴重不良反應事件。
*許多不良反應事件經調查後, 往往變成不符合被列為嚴重的標準，或, 例如，結果變成不是真的過敏反應。在經過密切追踪和分析，那些一開始被通報為嚴重不良反應事件或過敏反應，在夲週的通報率可能會下降。
*嚴重不良反應事件的平均率 1比每10萬個劑量分佈，是根據幾年的數據來計算的。同時也計算所有已完成的免疫接種活動，疫苗總數使用量和不良反應事件的被通報，並所有對嚴重不良反應事件反應的調查已經完。隨著越來越多的H1N1型流感疫苗劑量的使用和進行更多的分析，更有意義的嚴重不良反應事件人數的比率將會出現。

此外，分析發現：

*不良反應事件的類型和頻率（包括嚴重和不嚴重）迄今報告的，與在臨床試驗中所見的以及哪些使用佐劑疫苗的其他國家所見的是一致的。
*最經常報導的事件並不嚴重，包括注射部位反應，噁心，嘔吐，頭暈，頭痛和發燒。
*嚴重的132宗個案中，除下文所述過敏，並未顯示任何具體模式的不良事件。 到目前已報告6人死亡而且正在調查中。
*目前有8個格林巴利綜合徵（GBS）的個案被報告（0.3每百萬劑分配）在接種疫苗注射後。 在接種H1N1病毒後 報告的6個個案仍在被調查中。
*格林巴利綜合徵（GBS）是一種急性疾病特點是突然的軟弱或麻痺發作（見格林巴利綜合徵Guillain-Barre Syndrome的常見問題）。每年在加拿大大約有600-700個格林巴利綜合徵（GBS）的新病例報告。原因包括食源性細菌，呼吸道感染包括例似流行性感冒病例, 和手術。
*自1997年以來，在12年中的年度流感疫苗接種活動中，共有79個GBS個案在接種流感疫苗後被報告。因接種流感疫苗而得到格林巴利綜合徵（GBS) 的風險是頂多每注射一百萬劑中有一個額外的案件發生。加拿大人因流行性感冒而發展成格林巴利綜合徵（GBS）的風險遠遠超過因接種疫苗注射後而發展成格林巴利綜合徵（GBS）的風險。
*雖然 8個被報告的格林巴利綜合徵（GBS）的個案則仍在調查中，這個數字較預期為少。根據因接種疫苗而產生的格林巴利綜合徵（GBS）的新病例的比率低於所預期的比率，一些有關格林巴利綜合徵（GBS）的顧慮尚未顯示與H1N1病毒的疫苗有關。
*超過一半的嚴重不良反應事件的報告，94，有過反應敏。為了做報告的目的, 使用了布賴頓協作(Brighton Collaboration)出版的過敏反應標準個案的訂定。這個報告數字所反映的案件是已經經過聯邦和/或省和地區公共衛生部門的審查，並附合了高水平的診斷確定性。
*H1N1病毒免疫接種後產生的過敏反應總頻率 是0.39每10萬劑分配，這並未超過在接受任何疫苗後所觀察的正常範圍。
*其中被報告的過敏反應的案件之一是致命的，正在被調查中。其他的個案被治療和康復了。
*有超過 380非嚴重的過敏反應案件通報給加拿大公共衛生局(PHAC)由一個多樣性的症狀和體徵所組成，包括蕁麻疹，腫脹，發紅或皮膚上出紅疹，嘴唇或舌頭的刺痛，喉嚨緊縮和/或困難呼吸和噁心。這些大多都發作在免疫接種幾分鐘內，並已及時的被診所工作人員治療了。

如有翻譯不妥之處, 請指正, 不勝感激!


Update: December 18, 2009

All vaccines authorized for use in Canada have been carefully tested for safety. The H1N1 flu vaccine has been authorized for use based on preliminary clinical trial data, and will continue to be monitored and tested as it is administered across the country.

The Public Health Agency of Canada (PHAC) and Health Canada, with the collaboration of provinces and territories, the Canadian Paediatric Society and a network of researchers are actively monitoring all adverse events following immunization to the H1N1 flu vaccine in Canada. This is a key component of the Government of Canada approach to ensuring vaccine safety that is used to produce regular reports on the safety of the H1N1 vaccine.

PHAC is using the existing system - the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS). CAEFISS is supported by healthcare professionals who report adverse events to their provincial/territorial public health offices, which then share the information with PHAC.

This existing system is supported by additional projects to provide more detailed data, specifically related to the H1N1 flu vaccine. These include:

* The Immunization Monitoring Program-Active (IMPACT) . IMPACT is made up of a network of paediatric teaching hospitals that report on serious adverse events following immunization in children. At each participating site, nurse monitors look for adverse events and report on any which follow immunization.
* A Severe Outcomes Surveillance (SOS) Network will mirror the IMPACT network but will monitor adult hospitalizations. This system can also be adapted to monitor for additional symptoms, diseases or disorders if necessary. This project is being funded by the PHAC/CIHR Influenza Research Network (PCIRN) .
* Additional PCIRN projects will monitor vaccine safety in various groups and settings, including children, Aboriginals, people living with HIV, healthcare workers and people with egg allergies.

The existing surveillance system and these additional projects will help PHAC monitor adverse events following immunization (AEFI), detect any possible signals of concern and determine which, if any, are possibly linked to vaccine.

There are internationally accepted definitions for post marketing surveillance of adverse events following medications or vaccines:

An adverse event following immunization (AEFI) is any unwanted medical reaction following immunization. The majority of adverse events are not serious and include soreness, swelling or redness at the injection site, fever, rash, headache or muscle aches and pains.

A serious adverse event following immunization is any adverse event that is life-threatening, or results in death, requires hospitalization, prolongs an existing hospitalization or results in residual disability.

Serious adverse events following immunization are rare. In any immunization campaign, from regular childhood vaccines to seasonal flu shots, the reported rate of serious adverse events is on average about 1 case for every 100,000 doses distributed.

The 1 in 100,000 rate is based on tens of millions of vaccine doses distributed over several years. This rate is based on the administration of several different types of vaccines, some of which have higher or lower rates of adverse events. Rates can also vary by age. For more information, visit our vaccine safety and surveillance Frequently Asked Questions.

Regular reporting from these sources provides an early warning system that can help PHAC officials identify whether there is any need for further investigation to ensure vaccine safety.

This report contains data on the total aggregate numbers of adverse events reported to PHAC by provinces and territories and other sources. It provides a breakdown on the number of reported serious adverse events as well as selected serious adverse events of special importance, such as anaphylaxis (a severe allergic reaction) and the overall rate of adverse event reporting per 100,000 doses of vaccine distributed in Canada.

Reporting an adverse event does not mean that the vaccine was the cause. Careful investigation is needed to determine whether an event is directly linked to the vaccine or not. The number of adverse events and serious adverse events reported in the weekly snapshot are subject to further investigation and may change over time. The risk of the flu far outweighs the risk of vaccination.

Weekly Snapshot

As of December 5, 2009, 21.109 million doses of three types of vaccine had been distributed across Canada:

* Arepanrix (adjuvanted H1N1 flu vaccine from GlaxoSmithKline)
* Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without adjuvant from GlaxoSmithKline)
* Panvax (unadjuvanted H1N1 flu vaccine from CSL Australia)

Since the start of the H1N1 flu vaccine campaign through December 5, a total of 4,331 adverse events have been reported to provincial and territorial immunization programs of which 132 met one or more of the criteria to be considered serious. Eighty-four cases of anaphylaxis are included among the serious adverse events.

The reporting rate of adverse events per 100,000 doses distributed is 20.5. The reporting rate of serious adverse events is 0.63 per 100,000 doses distributed. To date, the overall frequency of anaphylaxis following H1N1 immunization is 0.40 per 100,000 doses distributed, which does not exceed the normal range observed after receiving any vaccine.
Analysis

Detailed review of the surveillance data to this point continues to support the safety of the vaccine. The overall reporting rate of adverse events is higher than for the seasonal influenza vaccine, while the reporting rate for serious adverse events is consistent with the average reporting rate of about 1 case for every 100,000 doses distributed. Several factors contribute to reporting rates for the H1N1 influenza vaccines, including:

* Heightened awareness around the H1N1 flu vaccine means that frontline healthcare workers have increased their vigilance and are reporting more potential adverse events. Increased surveillance in hospitals has also generated more reports.
* The one clearly recognized serious adverse event risk for immunization is anaphylaxis, a severe allergic reaction that generally occurs within minutes of vaccination, while the vaccine recipient is at the vaccination clinic. Cases of anaphylaxis are the most consistently reported and most easily measured serious adverse event.
* Upon investigation, many adverse events turn out not to meet the criteria for being classified as serious, or, for example, do not turn out to be true anaphylaxis. As closer follow-up and analysis is done on cases initially reported as serious adverse events or anaphylaxis, the rates may fall as was the case this week.
* The average rate of serious adverse events, which is 1 per 100,000 doses distributed, has been calculated based on several years of data. It is also calculated on completed immunization campaigns, when we have total numbers of vaccine distributed and adverse events reported, and all investigations into serious adverse events have been completed. As more doses of H1N1 vaccine are distributed and more analysis is conducted, a more meaningful number on the rate of serious adverse events will emerge.

In addition, the analysis has found that:

* The types and frequency of adverse events (both serious and non-serious) reported to date are consistent with what was seen in clinical trials, and what has been seen in other countries where the adjuvanted vaccine is being used.
* The most frequently reported events were not serious and included injection site reactions, nausea, vomiting, dizziness, headache and fever.
* The 132 serious reported cases, other than anaphylaxis as described below, do not reveal any specific pattern of adverse event. Six deaths have been reported to date and are under investigation.
* There were fewer serious cases of AEFI in this update as provinces and territories have been following up in detail on their previously reported cases and found that some of them did not meet the definition of serious.
*
* There have been 6 cases of Guillain-Barre Syndrome (GBS) reported to date (0.3 per million doses distributed) following vaccination. The 6 cases reported following vaccination with the H1N1 vaccine are still under investigation.
* GBS is an acute illness characterized by sudden onset of weakness or paralysis (see Guillain-Barre Syndrome Frequently Asked Questions). There are about 600-700 new cases of GBS reported in Canada per year. Causes include foodborne bacteria, respiratory infections including influenza-like illness, and surgery.
* Since 1997, during 12 annual season influenza vaccine campaigns, a total of 79 cases of GBS have been reported following influenza vaccine. The risk of getting GBS after getting the flu shot is, at most, one extra case per 1 million doses administered. Canadians are at far greater risk of developing GBS after getting the flu than they are after getting a flu shot.
* While the 6 cases reported are still under investigation, this number is less than expected. Based on the lower than expected rate of new cases of GBS following vaccination, concerns about GBS have not emerged in connection with H1N1 vaccines.
* More than half of the serious adverse events reported, 84, were anaphylaxis. For reporting purposes a standard case definition of anaphylaxis is used, as published by the Brighton Collaboration. The number of reports reflects cases that have been reviewed by federal and/or provincial and territorial public health authorities and that met a high level of diagnostic certainty.
* The overall frequency of anaphylaxis following H1N1 immunization is 0.40 per 100,000 doses distributed, which does not exceed the normal range observed after receiving any vaccine.
* One of the reported cases of anaphylaxis was fatal and is being investigated. The others were treated and recovered.
* There were more than 380 reports to PHAC of non-serious allergic reactions consisting of a variety of symptoms and signs including hives, swelling, redness or rash on the skin, tingling of the lips or tongue, a tightness in the throat and/or difficulty breathing, and nausea. These have onset mostly within minutes of immunization and have been treated promptly by clinic staff.

www.publichealth.gc.ca
Home > H1N1 Flu Virus > H1N1 Flu Vaccine Information > Vaccine Surveillance Report - Adverse Events following Immunization

每週特寫

截至12月12日，2009年，2407.1萬劑量的3種疫苗已經分佈在加拿大：

* Arepanrix（混合型H1N1流感疫苗由葛蘭素史克）一(混合型=佐劑型)
*甲型流感（H1N1）2009大流行的單價疫苗（無佐劑由葛蘭素史克）
* Panvax（非混合型H1N1流感疫苗的流動通訊澳大利亞）一(非混合型=無佐劑型)

打從H1N1流感疫苗注射活動開始，一直到 12月12日，共有4995不良反應事件已通報給省和地區的免疫計劃，其中 155 案件中符合了一個或一個以上的規定條件而被認定為嚴重。而 94例過敏案件則被包括在嚴重的不良反應事件其中。

本報告的不良反應率每10萬個劑量分佈是20.8。該報告率嚴重不良反應事件是0.64每10萬劑量分佈。迄今為止，H1N1病毒免疫接種後產生過敏總頻率每10萬個劑量分佈是為0.39，不超過在接受任何疫苗後所觀察到的正常範圍。

Weekly Snapshot

As of December 12, 2009, 24.071 million doses of three types of vaccine had been distributed across Canada:

* Arepanrix (adjuvanted H1N1 flu vaccine from GlaxoSmithKline)
* Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without adjuvant from GlaxoSmithKline)
* Panvax (unadjuvanted H1N1 flu vaccine from CSL Australia)

Since the start of the H1N1 flu vaccine campaign through December 12, a total of 4,995 adverse events have been reported to provincial and territorial immunization programs of which 155 met one or more of the criteria to be considered serious. Ninety-four cases of anaphylaxis are included among the serious adverse events.

The reporting rate of adverse events per 100,000 doses distributed is 20.8. The reporting rate of serious adverse events is 0.64 per 100,000 doses distributed. To date, the overall frequency of anaphylaxis following H1N1 immunization is 0.39 per 100,000 doses distributed, which does not exceed the normal range observed after receiving any vaccine.

[Mary Lee]

RE: Guillian-Barré Syndrome (GBS): GBS rates increased during the U.S swine flu vaccine campaign in 1976. The institutes of Medicine ruled that was no conclusive evidence linking this increase to the vaccine. During the campaign the incidence of this rare neurological disorder when from 1 in 100.000 to 2 in 100.000. This increase led to suspension of program. To recognize any increase in GBS rates. Canada has established a reporting network of neurologists to actively investigate and assess any and all new cases of GBS that occur to assess any relationship to vaccine receipt (Personal communication, Dr. Barbara Law, Chief of Vaccine Safety, PHAC).

[鐵桿一元]

乎恁辛苦ㄚ

[Mary Lee]

For reliable information on pH1N1 vaccine and more, visit.
www.immunizebc.ca
www.bccdc.ca
www.gov.bc.ca/h1n1
www.his.gov.bc.ca/pho/physh1n1.html

以上是加拿大官方網站有關H1N1資料。
我剛上完大夜班回到家, 等我睡醒後再継續找相關資料。待會見!

[娃娃凱（阿凱）]

請大家轉貼~謝謝…